Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

RCT: Among critically ill patients with Covid-19, treatment with an antiplatelet agent had a low likelihood of improving organ support–free days within 21 days.

23 Mar, 2022 | 10:38h | UTC

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA

Commentary: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London

 

Commentaries on Twitter

https://twitter.com/JAMA_current/status/1506188937852858369

 

Cohort Study: Perinatal complications in individuals in California with or without SARS-CoV-2 infection during pregnancy.

23 Mar, 2022 | 10:33h | UTC

Perinatal Complications in Individuals in California With or Without SARS-CoV-2 Infection During Pregnancy – JAMA Internal Medicine

News Release: Coronavirus may double severe complications in pregnancy – Kaiser Permanente

Commentary: COVID-19 in pregnancy tied to poor maternal outcomes, preterm birth, fetal death – CIDRAP

 

Cohort Study: Risks and burdens of incident diabetes in long COVID.

23 Mar, 2022 | 10:32h | UTC

Risks and burdens of incident diabetes in long COVID: a cohort study – The Lancet Diabetes & Endocrinology

 

The incidence of ocular complications in candidemic patients and implications for the practice of routine eye exams.

23 Mar, 2022 | 09:50h | UTC

The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine Eye Exams – Open Forum Infectious Diseases

 

New WHO guidelines on the management of tuberculosis in children and adolescents.

22 Mar, 2022 | 09:52h | UTC

WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents – World Health Organization

Commentary: New Children’s TB Guidelines a ‘Game-Changer’ With Non-Invasive Tests, Shortened Treatments – Health Policy Watch

Related: RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.

 

Review: When to operate after SARS-CoV-2 infection?

22 Mar, 2022 | 09:44h | UTC

When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA – Langenbeck’s Archives of Surgery

Related:

Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

 

Preventing and treating the common cold: what’s the evidence?

22 Mar, 2022 | 08:56h | UTC

Preventing and treating the common cold: what’s the evidence? – Evidently Cochrane

 

Commentary on Twitter

https://twitter.com/CochraneUK/status/1505978560078659587

 

Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care.

22 Mar, 2022 | 08:01h | UTC

Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care – JAMA Pediatrics

Editorial: Genetic Testing in Newborns Moves From Rare to Routine Application

 

Commentary on Twitter

 

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity.

21 Mar, 2022 | 09:47h | UTC

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity – Nature Reviews Microbiology

 

Commentary on Twitter

 

Infographic: IDSA COVID-19 outpatient treatment guidelines roadmap.

21 Mar, 2022 | 09:51h | UTC

COVID-19 Outpatient Treatment Guidelines Roadmap – Infectious Diseases Society of America

 

Commentary on Twitter

 

CDC Report: Effectiveness of mRNA vaccination in preventing COVID-19–associated invasive mechanical ventilation and death in the US.

21 Mar, 2022 | 09:38h | UTC

Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

Related Study: COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

Commentary: Studies show vaccines protect against serious Omicron illness – CIDRAP

 

Commentary on Twitter

 

Effectiveness of the Johnson & Johnson vaccine in health-care workers in South Africa in a period when the beta and then the delta SARS-CoV-2 variants of concerns were dominant.

21 Mar, 2022 | 09:43h | UTC

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study – The Lancet

Invited Commentary: Sisonke: reaching several goals together – The Lancet

 

Commentary on Twitter (thread – click for more)

 

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

21 Mar, 2022 | 09:37h | UTC

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel – JAMA

Related:

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

A validated score for evaluating spinal instability to assess surgical candidacy in active spinal tuberculosis—an evidence based approach and multinational expert consensus study.

21 Mar, 2022 | 08:21h | UTC

A Validated Score for Evaluating Spinal Instability to Assess Surgical Candidacy in Active Spinal Tuberculosis—An Evidence Based Approach and Multinational Expert Consensus Study – Global Spine Journal

 

M-A: Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxemic respiratory failure.

18 Mar, 2022 | 09:32h | UTC

Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Invited Commentary: The pandemic and the great awakening in the management of acute hypoxaemic respiratory failure – The Lancet Respiratory Medicine

Related:

[Preprint] RCT: In hypoxic but not critically ill patients with COVID-19, an intervention to increase prone positioning did not improve outcomes.

RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

 

Study finds no increased risk of rare neurological events after covid vaccination.

18 Mar, 2022 | 09:31h | UTC

News Release: Study finds no increased risk of rare neurological events after covid vaccination – BMJ Newsroom

Original Study: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis – The BMJ

Editorial: The neurological safety of covid-19 vaccines

 

Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines.

18 Mar, 2022 | 09:28h | UTC

Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines – BMJ Evidence-Based Medicine

News Release: Researchers find equitable COVID-19 vaccine distribution can target risks in different geographical areas – University of New Mexico

 

Commentary on Twitter

 

RCT: Oral contezolid vs. linezolid in adults with complicated skin and soft tissue infections.

18 Mar, 2022 | 07:54h | UTC

A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections – Journal of Antimicrobial Therapy (link to abstract – $ for full-text)

 

Commentary on Twitter

 

M-A: Comparative efficacy and safety of pharmacological interventions to prevent Mother-to-Child transmission of hepatitis B virus.

18 Mar, 2022 | 07:37h | UTC

Comparative efficacy and safety of pharmacological interventions to prevent Mother-to-Child transmission of hepatitis B virus: A systematic review and network meta-analysis – American Journal of Obstetrics & Gynecology

 

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

17 Mar, 2022 | 09:26h | UTC

2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Commentaries:

ACC Issues Clinical Guidance on CV Consequences of COVID-19 – American College of Cardiology

ACC Releases Guidance on CV Issues With COVID-19 – TCTMD

Key Points: 2022 ACC Decision Pathway on Cardiovascular Sequelae of COVID-19

Related:

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 

Commentary on Twitter (thread – click for more)

 

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

17 Mar, 2022 | 09:12h | UTC

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine

Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

 

Treatments for moderate to severe COVID-19: Cochrane evidence.

17 Mar, 2022 | 09:19h | UTC

Treatments for moderate to severe COVID-19: Cochrane evidence – Evidently Cochrane

 

Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.

17 Mar, 2022 | 09:10h | UTC

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study – The Lancet

Commentary: Evaluating COVID-19 vaccines in the real world – The Lancet

 

Treatments for mild COVID-19: Cochrane evidence.

17 Mar, 2022 | 09:17h | UTC

Treatments for mild COVID-19: Cochrane evidence – Cochrane Library

 

Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.

17 Mar, 2022 | 08:16h | UTC

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Author Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Related:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.